BioSpace News Archive

Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced several pipeline advancements and partnership updates.

Orpyx® Medical Technologies Inc. (Orpyx), a digital health company focused on extending the health span of patients with diabetes, announced the launch of the Orpyx SI® Flex Sensory Insole system and Orpyx Remote Patient Monitoring (RPM) services.

A new Health Trends® study from Quest Diagnostics developed in collaboration with the CDC found that the rate of hepatitis C antibody screening increased 145% in pregnant people during the decade-long study period ending June 2021.

BeiGene Announces BRUKINSA ™ (zanubrutinib) Is Approved in 50 Markets.

SI-BONE, Inc. (SIBN), (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced an FDA clearance for iFuse-TORQ ® for pelvic fracture fixation, including acute, non-acute and non-traumatic fractures.

Surrozen, Inc. today announced that the first subject has been dosed in its two-part Phase 1 clinical trial for SZN-043 which is in development for the potential treatment of severe alcoholic hepatitis.

Sirona Biochem Corp. is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company, pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for TFC-1067 and related family of compounds.

SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced it has signed a licensing agreement with OncoHost, a global leader in next-generation precision oncology for personalized cancer therapy.

Global Blood Therapeutics, Inc. announced results from the Sickle Cell Health Awareness, Perspectives and Experiences survey, a multinational survey on the burden of sickle cell disease and unmet needs as reported by more than 1,300 patients, caregivers and healthcare professionals in 10 countries.

Mustang Bio, Inc. announced that updated interim data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy, show a favorable safety profile, high overall response and complete response rates, and CAR T persistence in patients with follicular lymphoma.